Population

PRO MUJER NAMES CARMEN CORREA AS ITS CEO

Retrieved on: 
Wednesday, January 19, 2022 - 10:04pm

NEW YORK, Jan. 19, 2022 /PRNewswire/ --Pro Mujer, a social enterprise with more than31 years working to advance gender equality in Latin America, announces Carmen Correa as its new CEO.

Key Points: 
  • NEW YORK, Jan. 19, 2022 /PRNewswire/ --Pro Mujer, a social enterprise with more than31 years working to advance gender equality in Latin America, announces Carmen Correa as its new CEO.
  • Correa joined Pro Mujer in 2017 as the Director of Alliances.
  • In her new role, Correa will lead Pro Mujer and expand the organization's impact to bring it closer to its goal of achieving gender equality in Latin America.
  • Maria Cavalcanti will continue to be part of Pro Mujer, supporting and advising on strategic initiatives after six successful years as the CEO.

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

Retrieved on: 
Wednesday, January 19, 2022 - 9:49pm

The FDAs orphan drug designation underscores MT-601s potential as a treatment for pancreatic cancer, a cancer typically diagnosed at an incurable advanced stage with a total overall 5-year survival rate of 10%, said Peter L. Hoang, President & CEO of Marker Therapeutics.

Key Points: 
  • The FDAs orphan drug designation underscores MT-601s potential as a treatment for pancreatic cancer, a cancer typically diagnosed at an incurable advanced stage with a total overall 5-year survival rate of 10%, said Peter L. Hoang, President & CEO of Marker Therapeutics.
  • Marker developed MT-601, a new product targeting six tumor-associated antigens (PRAME, NY-ESO-1, Survivin, MAGE-A4, SSX2, WT1) highly expressed in pancreatic cancer.
  • The Company plans to file an Investigational New Drug Application (IND) for MT-601 for the treatment of pancreatic cancer in 2022.
  • The granting of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval.

Omicron Variant Having Significant Impact on Canada’s Economic Recovery

Retrieved on: 
Wednesday, January 19, 2022 - 8:43pm

The pandemics most contagious wave yet is having a significant impact on Canadas economic recovery, said Pedro Antunes, Chief Economist, The Conference Board of Canada.

Key Points: 
  • The pandemics most contagious wave yet is having a significant impact on Canadas economic recovery, said Pedro Antunes, Chief Economist, The Conference Board of Canada.
  • The economy should return to its potential output by the beginning of 2023 when population aging and anemic business investment will slow growth sharply.
  • Both inflation and Omicron are key factors that could accelerate or moderate our assumed timeline of interest rate hikes.
  • Globally, the ongoing pandemic is having a similar impact as it is in Canada.

National Headache Foundation Position Statement on the Treatment of Migraine

Retrieved on: 
Wednesday, January 19, 2022 - 8:13pm

Chicago, IL, Jan. 19, 2022 (GLOBE NEWSWIRE) -- For more than 50 years, the National Headache Foundation (NHF) has been the voice for more than 40 million American adults with migraine.

Key Points: 
  • Chicago, IL, Jan. 19, 2022 (GLOBE NEWSWIRE) -- For more than 50 years, the National Headache Foundation (NHF) has been the voice for more than 40 million American adults with migraine.
  • Unfortunately, the current care models adopted by payers (health insurance) have not kept pace with the many advances in treatment.
  • The vision of the National Headache Foundation (NHF) is a world without headache.
  • In the future, NHF will expand upon this Position Statement and propose specific treatment guidelines.

Carvana Leads Industry as Fastest to Sell One Million Vehicles Online Since Founding

Retrieved on: 
Wednesday, January 19, 2022 - 6:40pm

Announced today, Carvana (NYSE: CVNA), the leading e-commerce brand for buying and selling used cars, is the fastest to sell one million vehicles online in nine years and the fastest used car retailer ever to organically sell over 400,000 vehicles in one year.

Key Points: 
  • Announced today, Carvana (NYSE: CVNA), the leading e-commerce brand for buying and selling used cars, is the fastest to sell one million vehicles online in nine years and the fastest used car retailer ever to organically sell over 400,000 vehicles in one year.
  • Founded in 2012 and based in Phoenix, Carvanas (NYSE: CVNA) mission is to change the way people buy and sell cars.
  • By removing the traditional dealership infrastructure and replacing it with technology and exceptional customer service, Carvana offers consumers an intuitive and convenient online car buying, selling, and financing platform.
  • For further information on Carvana, please visit www.carvana.com , or connect with us on Facebook , Instagram , Twitter or the Carvana Blog .

Habi Acquires Mexico’s Marketplace Propiedades.com and Broker, iBuyer Tu Canton, Consolidating its Position as Spanish-LatAm’s Leading Real Estate Technology Company

Retrieved on: 
Wednesday, January 19, 2022 - 6:30pm

Habi , the data-driven residential platform, today announced the acquisition of OKOL, the parent company of Mexican marketplace Propiedades.com and the broker and iBuyer Tu Canton .

Key Points: 
  • Habi , the data-driven residential platform, today announced the acquisition of OKOL, the parent company of Mexican marketplace Propiedades.com and the broker and iBuyer Tu Canton .
  • The strategic investment secures Habis position as the leading real estate technology company in Spanish-speaking Latin America, and accelerates its move into Mexico.
  • Propiedades.com brings technological infrastructure and data centralization to residential real estate in Mexico to make buying, selling and comparing homes easier.
  • Founded in 2019, Habi is a data-driven real estate company that is streamlining the traditionally opaque homebuying/selling and financing process in Latin America.

Vera Whole Health, Inc. Announces Commencement of the Tender Offer for All Outstanding Shares of Castlight Health, Inc.

Retrieved on: 
Wednesday, January 19, 2022 - 7:30pm

The tender offer is being made pursuant to the merger agreement (the "Merger Agreement") executed on January 4, 2022 and announced by Vera and Castlight on January 5, 2022.

Key Points: 
  • The tender offer is being made pursuant to the merger agreement (the "Merger Agreement") executed on January 4, 2022 and announced by Vera and Castlight on January 5, 2022.
  • Additionally, Castlight is filing a solicitation/recommendation statement on Schedule 14D-9 that will include the recommendation of Castlight's board of directors that Castlight's stockholders tender their shares in the tender offer.
  • The tender offer for the outstanding shares of common stock of Castlight has commenced.
  • Vera has filed a tender offer statement on Schedule TO with the SEC, and Castlight will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the offer.

Mobile Application Market to Value US$ 717 Bn by 2030; Notes TMR Study

Retrieved on: 
Wednesday, January 19, 2022 - 5:30pm

Transparency Market Research (TMR) has conducted a detailed analysis on various factors associated with the growth of the mobile application market .

Key Points: 
  • Transparency Market Research (TMR) has conducted a detailed analysis on various factors associated with the growth of the mobile application market .
  • The TMR analysts project the global market for mobile application to expand at a CAGR of 20.2% during the forecast period of 2020-2030.
  • The global mobile application market stood at US$ 113.8 Bn in 2020 and is prognosticated to reach US$ 717 Bn by 2030.
  • Novel startups are emerging in the e-learning apps space, which will propel the growth prospects of the mobile application market.

Mobile Application Market to Value US$ 717 Bn by 2030; Notes TMR Study

Retrieved on: 
Wednesday, January 19, 2022 - 5:30pm

ALBANY, N.Y., Jan. 19, 2022 /PRNewswire/ -- Mobile Internet penetration has increased significantly over the years. With high smartphone adoption and extensive mobile Internet penetration, the demand for mobile applications has scaled phenomenally. Based on these aspects, the mobile application market will observe substantial growth opportunities.

Key Points: 
  • Transparency Market Research (TMR) has conducted a detailed analysis on various factors associated with the growth of the mobile application market .
  • The TMR analysts project the global market for mobile application to expand at a CAGR of 20.2% during the forecast period of 2020-2030.
  • The global mobile application market stood at US$ 113.8 Bn in 2020 and is prognosticated to reach US$ 717 Bn by 2030.
  • Novel startups are emerging in the e-learning apps space, which will propel the growth prospects of the mobile application market.

Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

Retrieved on: 
Wednesday, January 19, 2022 - 1:06am

The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).

Key Points: 
  • The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).
  • In March 2021, the DIAN-TU selected E2814, which was created from a research collaboration between Eisai and University College London, as the first investigational medicine among anti-tau drugs for the Tau NexGen study.
  • With increasing evidence from clinical studies showing that targeting amyloid can reduce biomarkers of AD, the Tau NexGen clinical trial leaders selected Eisai's investigational anti-Abeta protofibril antibody lecanemab (BAN2401) as the background anti-amyloid therapy, and the study design was amended in November 2021.
  • In the Tau NexGen study, symptomatic participants will be administered anti-amyloid beta (Abeta) protofibril antibody lecanemab for six months before being randomly assigned to also receive the anti-tau drug or a placebo.